Adma Biologics Inc
Q2 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: +2.86%.
Did ADMA Beat Earnings? Q2 2025 Results
ADMA Biologics delivered a clean beat across both top and bottom lines in the second quarter of 2025, reporting earnings per share of $0.14 against a consensus estimate of $0.14, a 3.70% beat, while revenue of $121.98 million edged past the $121.77 million analyst forecast and rose 13.8% year over year. The headline growth understates the underlying momentum: stripping out a $12.60 million Medicaid rebate accrual reversal that boosted the year-ago period, organic revenue expanded roughly 29%. The primary engine behind the quarter's profitability was a richer mix of higher-margin immunoglobulin sales combined with manufacturing efficiencies, which lifted gross margin to 55.1% from 53.6%. A post-quarter $300 million debt refinancing further reduced interest costs, strengthening the company's financial footing heading into what management projects will be an accelerating second half. ADMA reaffirmed full-year 2025 revenue guidance of more than $500 million and its 2026 target of $625 million or more, with a longer-term pre-2030 revenue goal of at least $1.10 billion.
- Continued adoption and utilization of ASCENIV by physicians, payers, and patients
- More favorable mix of higher-margin immunoglobulin (IG) sales
- Operational efficiencies that reduced manufacturing costs
- Lower interest expense year-over-year
- Record high-titer plasma collections from both internal and external sources
“The second quarter was another highly productive period for ADMA, highlighted by strong year-over-year underlying revenue and earnings growth, adjusting for a prior-year non-recurring item. We are confidently reaffirming all previously issued financial guidance, with growth rates anticipated to accelerate significantly in the second half of 2025 and beyond. Importantly, we commenced commercial-scale manufacturing with our FDA-approved yield enhancement process, and initial production batches are delivering the anticipated 20%+ increase in finished IG output. The successful initiation of yield-enhanced manufacturing marks a key inflection point—driving expected gross margin expansion, reinforcing ADMA's forecasted growth trajectory, and positioning the Company for an accelerating pace of revenue and earnings growth in the periods ahead.”
ADMA Biologics CEO, on the earnings call
Forward Guidance & Outlook
ADMA reaffirmed all FY 2025-2026 financial guidance: FY 2025 total revenue more than $500 million, FY 2026 total revenue of $625 million or more; FY 2025 Adjusted Net Income more than $175 million, FY 2026 of $245 million or more; FY 2025 Adjusted EBITDA more than $235 million, FY 2026 of $340 million or more. Pre-2030 total annual revenue is projected to reach $1.1 billion or more, with outsized earnings growth expected from current margin levels. Growth is expected to accelerate significantly in the second half of 2025 and beyond, driven by yield-enhanced manufacturing (which remains excluded from 2025 guidance and conservatively reflected in 2026 projections). SG-001 and potential capacity expansion from the new Boca Raton facility represent additional upside not yet included in the $1.1B+ pre-2030 revenue outlook. If successful, SG-001 could contribute $300–500 million or more in high-margin annual revenue.
ADMA YoY Financials
ADMA Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.